MedTrace Logo

Circulating Tumor DNA in Soft Tissue Sarcoma

NCT03818412 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-03-22

No results posted yet for this study

Summary

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.

Conditions

  • Soft Tissue Sarcoma

Interventions

PROCEDURE

Archival tumor tissue collection and blood draws

Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.

Sponsors & Collaborators

  • Mount Sinai Hospital, Canada

    collaborator OTHER

  • The Hospital for Sick Children

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Albiruni Razak, M.D. · Princess Margaret Cancer Centre

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2024-12-17
Completion
2025-01-17

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818412 on ClinicalTrials.gov